Courtney Arianne Washington, DO Introduction Losing weight is one thing, but losing fat while preserving muscle is the real challenge
Sensitivity landmark analyses stratified by timeframe of semaglutide initiation Given that semaglutide was initially approved for type 2 diabetes, with initial obesity approval in 2021, it is possible that inclusion of non-diabetic patients could introduce indication bias in the previously described analyses, as non-diabetic patients enrolled before 2021 likely represent off-label use and may differ systematically from those treated after approval
PlexusDx uses evidence-based, graduated escalation to balance speed with tolerability
The diabetes drug Ozempic has experienced worldwide shortages this year as an off-label weight loss tool, highlighting the huge popularity of pharmaceutical weight loss treatments
doi: 10.1158/1538-7445.AM2023-735
In recent years, we've dedicated thousands of hours toward understanding the best supplemental approaches to improving testosterone levels